Long-term data from clinical trials of various PARP inhibitors demonstrate a sustained response primarily in cancer patients with BRCA1/2 mutations, albeit the majority of patients inevitably develop resistance to platinum-based and/or PARP inhibitor therapy[79]. This evidence concerns the gene BRCA1 and cancer.